Oropharyngeal K kingae may predict osteoarticular infection

Article

A study in 123 children aged from 6 to 48 months with atraumatic osteoarticular symptoms confirmed investigators’ hypothesis that oropharyngeal carriage of Kingella kingae in children aged younger than 48 months with acute osteoarticular infection (AOI) is strong evidence that this microorganism is responsible.

A study in 123 children aged from 6 to 48 months with atraumatic osteoarticular symptoms confirmed investigators’ hypothesis that oropharyngeal carriage of Kingella kingae in children aged younger than 48 months with acute osteoarticular infection (AOI) is strong evidence that this microorganism is responsible.

Children with joint pain, a limp, or restricted limb movement and no history of trauma were included in the study. In addition to undergoing a clinical evaluation and radiologic investigations, all participants provided an oropharyngeal swab, synovial fluid, bone biopsy specimen, and peripheral blood samples investigators analyzed with a real-time polymerase chain reaction (PCR) assay specific to K kingae.

Forty patients received a diagnosis of AOI, as confirmed by microbiologic studies or magnetic resonance imaging. In 30 (75%) of these patients, K kingae was identified as the causative organism by PCR or culture of bone, joint, or blood specimen. All 30 patients also had oropharyngeal PCRs positive for K kingae. Investigators determined that sensitivity of the oropharyngeal swab PCR assay for K kingae was 100%, with specificity of 90.5% (Ceroni D, et al. Pediatrics. 2013;131[1]:e230-e235).

Commentary

With improved culture techniques and molecular diagnostic tools, the role of this pathogen in bone and joint infections is coming into focus. From 8% to 12% of young children have asymptomatic nasopharyngeal colonization with K kingae. It is thought that some colonized children develop bacteremia with the organism, allowing seeding of joints or bone in a few. Knowledge of the organism is important because K kingae osteoarticular infection may have a subtler, insidious onset than infection caused by Staphylococcus aureus, and ideal treatment differs; typically K kingae is resistant to clindamycin.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
Potential downstream benefits of RSV preventive measures, with Octavio Ramilo, MD
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention | Image Credit: St. Jude Children's Research Hospital
Tina Tan, MD, comments on FDA expanded approval for MenQuadfi meningococcal disease vaccine
Tina Tan, MD, discusses impact of FDA's stricter COVID-19 vaccine policy for children
Related Content
© 2025 MJH Life Sciences

All rights reserved.